Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.78 |
| ▸ | PRKACA | P17612 | 4/20 | 0.77 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.77 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.77 |
| ▸ | PRKCG | P05129 | 3/20 | 0.77 |
| ▸ | CDK1 | P06493 | 3/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.77 |
| ▸ | GSK3A | P49840 | 3/20 | 0.77 |
| ▸ | GSK3B | P49841 | 3/20 | 0.77 |
| ▸ | PRKX | P51817 | 3/20 | 0.77 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.77 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.77 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.77 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.77 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.77 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.77 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.77 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.77 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.77 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6853456 | 1.00 | CHEK1 (0.78) | CHEK1PRKACAPRKD3MAP4K4PRKCG | |
| SCHEMBL6853458 | 1.00 | CHEK1 (0.78) | CHEK1PRKACAPRKD3MAP4K4PRKCG | |
| SCHEMBL6849881 | 0.94 | CHEK1 (0.82) | CHEK1PRKACAPRKD3MAP4K4PRKCG | |
| SCHEMBL6849875 | 0.94 | CHEK1 (0.82) | CHEK1PRKACAPRKD3MAP4K4PRKCG | |
| SCHEMBL6849880 | 0.94 | CHEK1 (0.82) | CHEK1PRKACAPRKD3MAP4K4PRKCG | |
| SCHEMBL6925977 | 0.94 | CHEK1 (0.82) | CHEK1PRKACAPRKD3MAP4K4PRKCG | |
| SCHEMBL6857674 | 0.90 | CHEK1 (0.80) | CHEK1PRKACAPRKD3MAP4K4PRKCG | |
| SCHEMBL7069636 | 0.90 | CHEK1 (0.80) | CHEK1PRKACAPRKD3MAP4K4PRKCG | |
| SCHEMBL6857672 | 0.90 | CHEK1 (0.80) | CHEK1PRKACAPRKD3MAP4K4PRKCG | |
| SCHEMBL6857670 | 0.90 | CHEK1 (0.80) | CHEK1PRKACAPRKD3MAP4K4PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | claimed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | claimed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | claimed |
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | CHEK1 53/4885PRKACA 27/4885PRKD3 227/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | CHEK1 53/4885PRKACA 27/4885PRKD3 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.